2018 BioPacific Conference (20th Annual Conference of CABS) Agenda
Theme: Innovation, Collaboration and Globalization
San Mateo Marriott, 1770 South Amphlett Blvd, San Mateo, CA 94402
| 8:00 AM – 8:45 AM | REGISTRATION |
| 8:45 AM – 8:50 AM | Welcome Remarks Yan Wang, PhD, President-elect of CABS and 2018 BioPacific Conference Organizing Committee Chair |
| 8:50 AM – 9:00 AM | State of the Society Alex J. Zhang, PhD, MBA, President of CABS |
| 9:00 AM – 9:30 AM | Combining Discreet Immune Mechanisms for Cancer Therapy: From Concept to Clinical Evidence Nils Lonberg, PhD, Senior VP, Oncology Discovery Biology, Bristol-Myers Squibb |
| 9:30 AM – 10:00 AM | In-China-for-Global Biologics: The Exciting Story of WuXi Biologics Chris Chen, PhD, CEO, WuXi Biologics |
| 10:00 AM-10:15 AM – Coffee Break | |
| 10:15 AM-10:55 AM | CABS K. Fong Award in Life Sciences Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures Awardees: Guoliang Yu, PhD, Executive Chairman, Crown Bioscience; Venture Partner, OrbiMed Venture Yuling Luo, PhD, Founder, Chairman, and CEO of Alamar Biosciences |
| 10:55 AM – 11:15 AM | Fireside Chat: Moderator: Cheni Kwok, PhD, CLP, Managing Partner & Founder, Linear Dreams Yiding（Mike）Chen, Founder and CEO, ACROBiosystems Scott Liu, PhD, President and CEO, Shanghai Henlius Biotech, Inc. |
| 11:15 AM – 11:55 PM | IP Considerations, and Cross-border Licensing and Collaboration This session will cover intellectual property considerations in drug development and licensing deals; the stories of cross-border licensing deals and collaborations in drug and device development. Moderator, Janet Xiao, PhD, JD, Partner, Co-chair, Global Life Sciences Group, Morrison & Foerster Panelist, Li Feng, PhD, Partner, Finnegan Panelist, Tony Xue, PhD, CEO, Kelun-Biotech BioPharmaceutical Panelist, Wilson Lee, Director, United States, Sino-Singapore (Chengdu) Innovation Park Development Panelist, Steven X. Cui, PhD, JD, Owner, TransPac IP Panelist, Rufus Pichler, JD, Partner, Morrison & Foerster |
| 12:00 PM – 12:45 PM – Lunch Break | |
| 12:45 PM – 1:00 PM | Celebrating 20 years of CABS’s Excellence |
| 1:00 PM – 1:30 PM | Presentation title will be available later Sylvaine Cases, PhD, Vice President, Oncology Scientific Innovation, Janssen Pharmaceutical Companies of Johnson & Johnson |
| 1:30 PM – 2:00 PM | Innovations, Tools, and Animal Models in Drug Development This session will cover humanized animal model for immune checkpoint inhibitor evaluation; how to design clinical trial based on animal model; the importance of NGS and liquid biopsy in precision medicine and drug development; and affinity selection mass spectrometry as an innovative platform. Panelist, Brooke Rock, PhD, Principal Scientist, Amgen Panelist, Qingcong Lin, PhD, CEO, BioCytogen Boston Panelist, Tao Chen, Co-founder and CEO of Paragon Genomics Panelist, Xueheng (Shawn) Cheng, PhD, Chief Technology Officer, Viva Biotech Panelist, Liyu Wu, PhD, Senior Director, US Pharmaceutical Business Development and Project Management, Novogene |
| 2:00 PM – 2:30 PM | A world-class breakthrough in blood cancer treatment done by China biotech company Legend Biotech with CART cell therapy Li Zhu, PhD, Chief Strategy Officer, Nanjing Legend Biotech and GenScript Biotechnology |
| 2:30 PM – 3:00 PM | Developing Innovative Therapeutics This session will cover the program selection for drug development; clinical trial strategies on immune-oncology drug; companion diagnostics for a successful clinical trial. Panelist, Daniel Pierce, PhD, Senior Director of Translational Medicine, Celgene Panelist, John Ning, MD, PhD, Clinical Consultant in Clinical Science and Product Development Oncology for Genentech Panelist, Jingrong Li, PhD, VP of CMC/Manufacturing, CStone (Suzhou) Pharmaceuticals Panelist, Xiao-Jun Ma, PhD, Chief Scientific Officer, Advanced Cell Diagnostics Panelist, Nelson Lin, PhD, Director, Global Commercial Development, AbbVie |
| 3:00 PM – 3:15PM – Coffee Break | |
| 3:15 PM – 3:45 PM | The regulatory affairs after the enforcement of ICH guideline by CFDA and the comparison of regulatory affairs between China and US Dan Zhang, M.D., MA, MPH, Chairman, Fountain Medical Development (FMD) |
| 3:45 PM – 4:15PM | Harnessing potent immune agonist pathways for oncology and beyond Deborah Charych, PhD, Executive Director, Nektar Therapeutics |
| 4:15 PM – 4:50 PM | Panel Discussion: Investment, Acquisition and IPO in Life Sciences. This session will cover cross-border life science investment, Sanpower’s acquisition of Dendreon for $819.9 million; IPO in Hongkong vs. US. Moderator, Huijun Zhou, Ph.D., FACMG, Founder and CEO, iDNA Panelist, Jimmy Zhang, PhD, MBA, Venture Partner, Lilly Asia Ventures Panelist, Grace Xu, MBA, Chairperson, Dendreon; Senior Vice President, Sanpower Group Panelist, Angela Rusakova, Master of Economics, Partner, Deloitte & Touche Panelist, Rajeev Dadoo, PhD, MBA, Partner, SR One |
| 5:00 PM – Conference Adjourned | |
| 8:45 AM – 5:00 PM – Conference (Convene room) | |
| 8:45 AM – 5:00 PM – Partnering (Synergy 1 room) | |
| 8:00 AM – 6:00 PM – Exhibition hall (Inspire room) | |
| 5:00 PM – 7:00 PM – Post-conference Reception Sponsored by Diamond Sponsors (Engage room and courtyard) | |